Valproic Acid in Treating Patients With Kaposi's Sarcoma
Completed · Not applicable
Conditions studied: Sarcoma
In brief
RATIONALE: Valproic acid may help stop the growth of Kaposi's sarcoma cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This clinical trial is studying valproic acid in treating patients with HIV-related Kaposi's sarcoma.
Key facts
- Study ID
- NCT00075777
- Run by
- AIDS Malignancy Consortium
- People needed
- 19
- Starts
- 2005-02-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2014-08-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
- Veterans Affairs Medical Center - San Diego — San Diego, California, United States
- UCSF Comprehensive Cancer Center — San Francisco, California, United States
- Georgia Cancer Center for Excellence at Grady Memorial Hospital — Atlanta, Georgia, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Siteman Cancer Center at Barnes-Jewish Hospital — St Louis, Missouri, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- Albert Einstein Cancer Center at Albert Einstein College of Medicine — The Bronx, New York, United States
- Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- Joan Karnell Cancer Center at Pennsylvania Hospital — Philadelphia, Pennsylvania, United States
- Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.